TSPO Alzheimer's Disease PET Tracer Binding Genotyping Kit

The TSPO gene encodes an 18 kDa translocator protein on the mitochondrial outer membrane and is a key biomarker of neuroinflammatory activation. Genetic polymorphisms at specific loci directly affect the binding affinity between TSPO and PET tracers, thereby determining the accuracy and reliability of neuroinflammation imaging. In Alzheimer's disease research, although genotyping of this locus is not directly associated with disease susceptibility, it is decisive for TSPO-PET neuroinflammation imaging: approximately 30% of the population, due to low-affinity genotypes, cannot obtain valid imaging data with conventional tracers, potentially leading to biased neuroinflammation assessment or failed examinations. Pre-screening via an SNP genotyping detection kit can precisely identify high-, medium-, and low-affinity types, guiding clinicians to select appropriate tracers or perform signal correction, ensuring the accuracy of Alzheimer's disease neuroinflammation assessment and providing a reliable molecular imaging basis for early disease diagnosis, disease course monitoring, and anti-inflammatory treatment efficacy evaluation. With the development of novel cross-genotype tracers and the establishment of the ATN+I diagnostic framework, genotyping detection of this locus will become a standard pre-procedure for precise imaging diagnosis of Alzheimer's disease, playing a core value in early screening of neurodegenerative diseases, individualized treatment strategy development, and subject stratification in new drug clinical trials, promoting a comprehensive transformation of Alzheimer's disease from pathological diagnosis to the era of precision medicine.